DK2187882T3 - Behandling af progressiv neurodegenerativ sygdom med ibudilast - Google Patents

Behandling af progressiv neurodegenerativ sygdom med ibudilast

Info

Publication number: DK2187882T3
Authority: DK; Denmark
Prior art keywords: ibudilast; treatment; neurodegenerative disease; progressive neurodegenerative; progressive
Prior art date: 2007-07-11

Application number

DK08781498.4T

Other languages

English (en)

Inventor

Michael E Kalafer

Kenneth W Locke

Kazuko Matsuda

Richard E Gammans

Original Assignee

Medicinova Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-11

Filing date

2008-07-08

Publication date

2013-04-08

2008-07-08 Application filed by Medicinova Inc filed Critical Medicinova Inc

2013-04-08 Application granted granted Critical

2013-04-08 Publication of DK2187882T3 publication Critical patent/DK2187882T3/da

Links

ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 title 1
229960002491 ibudilast Drugs 0.000 title 1
230000004770 neurodegeneration Effects 0.000 title 1
208000015122 neurodegenerative disease Diseases 0.000 title 1
230000000750 progressive effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Dermatology (AREA)
Psychology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK08781498.4T 2007-07-11 2008-07-08 Behandling af progressiv neurodegenerativ sygdom med ibudilast DK2187882T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US92974507P	2007-07-11	2007-07-11
US4218108P	2008-04-03	2008-04-03
PCT/US2008/069417 WO2009009529A1 (en)	2007-07-11	2008-07-08	Treatment of progressive neurodegenerative disease with ibudilast

Publications (1)

Publication Number	Publication Date
DK2187882T3 true DK2187882T3 (da)	2013-04-08

Family

ID=39789775

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK08781498.4T DK2187882T3 (da)	2007-07-11	2008-07-08	Behandling af progressiv neurodegenerativ sygdom med ibudilast

Country Status (14)

Country	Link
US (10)	US8138201B2 (da)
EP (2)	EP2567699A1 (da)
JP (2)	JP5468001B2 (da)
CN (1)	CN101848712B (da)
AU (1)	AU2008275148A1 (da)
BR (1)	BRPI0814624A2 (da)
CA (2)	CA2970273C (da)
DK (1)	DK2187882T3 (da)
ES (1)	ES2402175T3 (da)
HR (1)	HRP20130057T1 (da)
PL (1)	PL2187882T3 (da)
PT (1)	PT2187882E (da)
TW (1)	TW200918051A (da)
WO (1)	WO2009009529A1 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2012530701A (ja) *	2009-06-19	2012-12-06	テバファーマシューティカルインダストリーズリミティド	多発性硬化症のラキニモドでの治療
WO2010151551A1 (en) *	2009-06-23	2010-12-29	Medicinova, Inc.	ENANTIOMERIC COMPOSITIONS OF 2-AMINO-1-(2-ISOPROPYLPYRAZOLO[1,5-a]PYRIDIN-3-YL)PROPAN-1-ONE AND RELATED METHODS
PL2458992T3 (pl) *	2009-07-30	2016-07-29	Teva Pharma	Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
WO2011019375A1 (en) *	2009-08-10	2011-02-17	Teva Pharmaceutical Industries Ltd.	Treatment of bdnf-related disorders using laquinimod
USRE49251E1 (en)	2010-01-04	2022-10-18	Mapi Pharma Ltd.	Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
HUE060304T2 (hu) *	2010-01-04	2023-02-28	Mapi Pharma Ltd	Glatiramer acetátot tartalmazó depó rendszer
CA2791711A1 (en) *	2010-03-03	2011-09-09	Teva Pharmaceutical Industries Ltd.	Treatment of lupus arthritis using laquinimod
SG183512A1 (en) *	2010-03-03	2012-09-27	Teva Pharma	Treatment of lupus nephritis using laquinimod
DK2542079T3 (da) *	2010-03-03	2014-08-25	Teva Pharma	Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat
WO2012143924A1 (en)	2011-04-21	2012-10-26	Mapi Pharma Ltd.	Random pentapolymer for treatment of autoimmune diseases
CA2851525A1 (en)	2011-10-12	2013-04-18	Teva Pharmaceutical Industries Ltd.	Treatment of multiple sclerosis with combination of laquinimod and fingolimod
CN104093310A (zh)	2012-02-03	2014-10-08	泰华制药工业有限公司	拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
CN103255142B (zh) *	2012-02-21	2017-07-25	上海转基因研究中心	一种利用RNAi调控内源性朊蛋白表达的方法及其应用
TW201400117A (zh)	2012-06-05	2014-01-01	Teva Pharma	使用拉喹莫德治療眼發炎疾病
CN103505731A (zh) *	2012-06-15	2014-01-15	中国药科大学	1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途
FR3000746A1 (fr)	2013-01-04	2014-07-11	Centre Nat Rech Scient	Peptide pour son utilisation dans le traitement des neuronopathies motrices
BR112015019564A2 (pt) *	2013-02-15	2017-07-18	Teva Pharma	tratamento de esclerose múltipla com laquinimod
WO2014178892A1 (en)	2013-05-03	2014-11-06	Scanlan Thomas S	Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
WO2015168103A1 (en)	2014-04-29	2015-11-05	Teva Pharmaceutical Industries Ltd.	Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
WO2015195822A1 (en) *	2014-06-20	2015-12-23	Medicinova, Inc.	A combination of geranylgeranylacetone and ibudilast and methods of using same
EP3193870A4 (en) *	2014-09-16	2018-04-25	Teva Pharmaceutical Industries Ltd.	Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod
KR102462638B1 (ko) *	2014-11-26	2022-11-03	메디시노바, 인크.	이부딜라스트와 릴루졸의 배합물 및 이의 사용방법
WO2016086000A1 (en) *	2014-11-26	2016-06-02	Medicinova, Inc.	A combination of geranygeranylacetone, ibudilast, and riluzole and methods of using same
CN105395511A (zh) *	2015-12-07	2016-03-16	黑龙江省智诚医药科技有限公司	一种异丁司特缓释微丸及其制备方法
WO2017196857A1 (en) *	2016-05-10	2017-11-16	Medicinova, Inc.	Treatment of alcoholism and depression and/or dysphoric mood using ibudilast
US12097292B2 (en)	2016-08-28	2024-09-24	Mapi Pharma Ltd.	Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh)	2016-08-31	2019-07-05	Mapi医药公司	包含醋酸格拉替雷的储库系统
WO2018119262A1 (en) *	2016-12-22	2018-06-28	Medicinova, Inc.	Methods of treating glioblastoma multiforme using ibudilast
CN110382052A (zh)	2017-03-26	2019-10-25	Mapi医药公司	用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
ES2959799T3 (es) *	2018-02-12	2024-02-28	Medicinova Inc	Métodos para suprimir células supresoras de origen mieloide en pacientes
JP2021512921A (ja)	2018-02-12	2021-05-20	メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ，Ｉｎｃ．	癌療法に対するイブジラストおよび第二の薬剤を使用した方法ならびに投与レジメン
WO2020076809A1 (en)	2018-10-09	2020-04-16	Medicinova, Inc.	Combination of ibudilast and interferon-beta and methods of using same
CN112804999B (zh) *	2018-10-19	2024-03-15	美迪诺亚公司	通过异丁司特治疗眼科疾病/病症或损伤的方法
AU2019397067A1 (en)	2018-12-12	2021-07-22	Autobahn Therapeutics, Inc.	Novel thyromimetics
US12350283B2 (en) *	2019-02-26	2025-07-08	Universitat De Valencia-Estudi General	Methods and compositions for treating motor neuron diseases
WO2020180624A1 (en)	2019-03-01	2020-09-10	Autobahn Therapeutics, Inc.	Novel thyromimetics
WO2020251748A1 (en) *	2019-06-11	2020-12-17	Yale University	Novel treatment for wolfram syndrome
EP4034090A1 (en)	2019-09-23	2022-08-03	MediciNova, Inc.	Ibudilast oral formulations and methods of using same
US12466781B2 (en)	2019-11-29	2025-11-11	Autobahn Therapeutics, Inc.	Thyromimetics
CA3174413A1 (en) *	2020-04-06	2021-10-14	Yuichi Iwaki	Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast
US12590072B2 (en)	2020-06-17	2026-03-31	Autobahn Therapeutics, Inc.	Thyromimetics
WO2021257851A1 (en)	2020-06-17	2021-12-23	Autobahn Therapeutics, Inc.	Thyromimetics
WO2022164948A1 (en)	2021-01-29	2022-08-04	Medicinova, Inc.	Methods of treating chemical gas exposure
US12005049B2 (en)	2021-07-26	2024-06-11	Medicinova, Inc.	Methods of preventing cancer metastasis
CA3231869A1 (en)	2021-09-21	2023-03-30	Medicinova, Inc.	Ibudilast in combination therapy for use in the treatment of glioblastoma
US12042485B2 (en)	2021-10-07	2024-07-23	Medicinova, Inc.	Methods of minimizing cancer metastasis
CN118973574A (zh)	2022-02-01	2024-11-15	美迪诺亚公司	异丁司特治疗新冠肺炎后遗症的用途
WO2023192885A2 (en) *	2022-03-28	2023-10-05	Praxis Precision Medicines, Inc.	Methods of using oligomeric compounds to treat scn2a-related disorders
US20240016729A1 (en)	2022-07-13	2024-01-18	Medicinova, Inc.	Injectable formulations of ibudilast
WO2026060180A1 (en)	2024-09-11	2026-03-19	Medicinova, Inc.	Modified release formulations of ibudilast

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6395747B1 (en) *	1998-08-10	2002-05-28	Sauro Sakoda	Remedies for multiple sclerosis
EP1343528A2 (en) *	2000-11-02	2003-09-17	Research Foundation of City University of New York	Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
US20050043319A1 (en) *	2001-08-14	2005-02-24	Exonhit Therapeutics Sa	Molecular target of neurotoxicity
DE602004031356D1 (de)	2003-11-21	2011-03-24	Zalicus Inc	Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
JP4954085B2 (ja)	2004-12-06	2012-06-13	メディシノバ，インコーポレイテッド	神経障害性疼痛及びその関連する症状を治療するためのイブジラスト
EP1940389A2 (en) *	2005-10-21	2008-07-09	Braincells, Inc.	Modulation of neurogenesis by pde inhibition

2008
- 2008-07-08 US US12/169,042 patent/US8138201B2/en active Active
- 2008-07-08 HR HRP20130057AT patent/HRP20130057T1/hr unknown
- 2008-07-08 JP JP2010516198A patent/JP5468001B2/ja active Active
- 2008-07-08 BR BRPI0814624-1A2A patent/BRPI0814624A2/pt not_active Application Discontinuation
- 2008-07-08 ES ES08781498T patent/ES2402175T3/es active Active
- 2008-07-08 CA CA2970273A patent/CA2970273C/en active Active
- 2008-07-08 PL PL08781498T patent/PL2187882T3/pl unknown
- 2008-07-08 WO PCT/US2008/069417 patent/WO2009009529A1/en not_active Ceased
- 2008-07-08 AU AU2008275148A patent/AU2008275148A1/en not_active Abandoned
- 2008-07-08 DK DK08781498.4T patent/DK2187882T3/da active
- 2008-07-08 PT PT87814984T patent/PT2187882E/pt unknown
- 2008-07-08 CA CA2693697A patent/CA2693697C/en active Active
- 2008-07-08 EP EP12196108A patent/EP2567699A1/en not_active Withdrawn
- 2008-07-08 CN CN200880106623XA patent/CN101848712B/zh active Active
- 2008-07-08 EP EP08781498A patent/EP2187882B1/en active Active
- 2008-07-10 TW TW097126065A patent/TW200918051A/zh unknown
2012
- 2012-02-22 US US13/402,702 patent/US8338453B2/en active Active
- 2012-12-21 US US13/725,627 patent/US9114136B2/en active Active
2013
- 2013-12-10 JP JP2013255214A patent/JP2014062118A/ja active Pending
2014
- 2014-02-24 US US14/188,061 patent/US9314452B2/en active Active
- 2014-09-19 US US14/491,939 patent/US20150011581A1/en not_active Abandoned
2016
- 2016-03-23 US US15/078,291 patent/US20170014390A1/en not_active Abandoned
- 2016-10-07 US US15/288,582 patent/US20170020851A1/en not_active Abandoned
2019
- 2019-05-01 US US16/400,844 patent/US11083713B2/en active Active
2021
- 2021-07-02 US US17/366,563 patent/US11944607B2/en active Active
2024
- 2024-03-29 US US18/621,850 patent/US20250073213A1/en active Pending

Also Published As

Publication number	Publication date
US20140171463A1 (en)	2014-06-19
US20120214839A1 (en)	2012-08-23
CA2970273A1 (en)	2009-01-15
TW200918051A (en)	2009-05-01
JP2010533193A (ja)	2010-10-21
PT2187882E (pt)	2013-04-17
CN101848712A (zh)	2010-09-29
EP2187882A1 (en)	2010-05-26
AU2008275148A1 (en)	2009-01-15
US20200093805A1 (en)	2020-03-26
PL2187882T3 (pl)	2013-05-31
JP5468001B2 (ja)	2014-04-09
US20170020851A1 (en)	2017-01-26
US8138201B2 (en)	2012-03-20
EP2187882B1 (en)	2013-01-09
CA2970273C (en)	2020-04-14
CA2693697A1 (en)	2009-01-15
US8338453B2 (en)	2012-12-25
US9114136B2 (en)	2015-08-25
US9314452B2 (en)	2016-04-19
WO2009009529A1 (en)	2009-01-15
US11944607B2 (en)	2024-04-02
EP2567699A1 (en)	2013-03-13
CA2693697C (en)	2017-07-25
JP2014062118A (ja)	2014-04-10
BRPI0814624A2 (pt)	2015-01-27
US20170014390A1 (en)	2017-01-19
US11083713B2 (en)	2021-08-10
US20130217718A1 (en)	2013-08-22
US20090062330A1 (en)	2009-03-05
US20220168283A1 (en)	2022-06-02
US20250073213A1 (en)	2025-03-06
CN101848712B (zh)	2013-07-24
US20150011581A1 (en)	2015-01-08
ES2402175T3 (es)	2013-04-29
HRP20130057T1 (hr)	2013-02-28

Publication	Publication Date	Title
DK2187882T3 (da)	2013-04-08	Behandling af progressiv neurodegenerativ sygdom med ibudilast
DK2222272T3 (da)	2013-02-11	Behandling af luftvejssygdom
DK2056807T3 (da)	2012-10-22	Behandling af inflammatoriske sygdomme
DK2440230T3 (da)	2021-01-18	Behandlingsregimener til behandling af neurologisk sygdom
DK3421603T3 (da)	2022-01-10	Genterapi for neurodegenerative forstyrrelser
EP2334277A4 (en)	2016-01-06	CRUTCH
DK3192520T3 (da)	2019-05-27	Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
BR112014010164A2 (pt)	2017-04-25	implante de tecido duro
BRPI0811265A2 (pt)	2014-09-30	Tratamento de sinucleinopatias
DK2111555T3 (da)	2013-09-02	Diagnosticering af præeklampsi
DK2627345T3 (da)	2014-09-01	Formuleringer til behandling af sygdomme i de øvre luftveje
BRPI0909221A2 (pt)	2015-08-11	Desordens neurodegenerativas
DK2004204T3 (da)	2013-01-07	Behandling af neurodegenerative sygdomme med selenat
BRPI0813670A2 (pt)	2014-12-30	Compostos para tratamento
DK2107870T3 (da)	2016-04-11	Lavement med reduceret irritationseffekt til behandling af inflammatorisk tarmsygdom
DK3276004T3 (da)	2020-04-06	Fremgangsmåder til behandling af kronisk nyresygdom
DK2358714T3 (da)	2012-08-20	Alkylcyclohexylethere af dihydrotetraazabenzoazulener
HUE033690T2 (hu)	2017-12-28	Terápiás szer hangulatzavarokra
DK2114147T3 (da)	2012-06-25	Reduktion af bivirkninger af tramadol
EP2110789A4 (en)	2010-12-01	PAPER MONEY PROCESSOR
BRPI1011535A2 (pt)	2016-03-29	tratamento de distúrbios resistentes à insulina.
BRPI0820410A2 (pt)	2015-05-19	Lactans substituídos terapêuticos
BRPI0818598A2 (pt)	2017-05-16	agentes terapêuticos - 802
DK2117565T3 (da)	2012-11-19	Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
DK2673363T3 (da)	2017-11-13	Behandling af angiogenesesygdomme